Gensight Biologics S.a annual ebitda
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a EBITDA Growth & History (SIGHT)
Gensight Biologics S.a's calculated EBITDA was −€8.7M for fiscal 2025.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −€8.7M | €6.1M | — |
| 2024 | 2024-12-31 | −€14.8M | €12.8M | — |
| 2023 | 2023-12-31 | −€27.5M | −€743,000 | — |
| 2022 | 2022-12-31 | −€26.8M | €424,000 | — |
| 2021 | 2021-12-31 | −€27.2M | −€3.2M | — |
| 2020 | 2020-12-31 | −€24.0M | — | — |
Gensight Biologics S.a ebitda trends
Over the last five fiscal years, Gensight Biologics S.a's ebitda increased from −€24.0M to −€8.7M, a change of €15.3M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...